Dr. Bennett is the executive vice president and chief scientific officer at Ionis Pharmaceuticals and one of the founding members of the company. He is responsible for continuing to advance Ionis’ technology and expanding the company’s drug discovery platform. Dr. Bennett is also the franchise leader for gene-editing programs at Ionis. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry.
Dr. Bennett has been recognized for his research with numerous awards. He is a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research, the 2021 Gabbay Award and the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen), and the inaugural Healy Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS). Dr. Bennett also received the 2018 Hereditary Disease Foundation's (HDF) Leslie Gehry Brenner Prize for Innovation in Science for his leadership and continued commitment to developing antisense therapies for Huntington's disease (HD).
Dr. Bennett has published more than 230 papers in the field of antisense research and development, and he is an inventor on more than 175 issued patents.
Prior to joining Ionis, Dr. Bennett was associate senior investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories (currently, GlaxoSmithKline).
He received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. He performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories.
Dr. Bennett serves on the Advisory Board for the Hereditary Disease Foundation and SAB for the McLaughlin Institute.
What is C. Frank Bennett's net worth?
The estimated net worth of C. Frank Bennett is at least $6.06 million as of March 3rd, 2026. Dr. Bennett owns 80,554 shares of Ionis Pharmaceuticals stock worth more than $6,061,689 as of May 6th. This net worth evaluation does not reflect any other assets that Dr. Bennett may own. Learn More about C. Frank Bennett's net worth.
How do I contact C. Frank Bennett?
Has C. Frank Bennett been buying or selling shares of Ionis Pharmaceuticals?
C. Frank Bennett has not been actively trading shares of Ionis Pharmaceuticals over the course of the past ninety days. Most recently, C Frank Bennett sold 85,089 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $79.23, for a transaction totalling $6,741,601.47. Following the completion of the sale, the executive vice president now directly owns 80,554 shares of the company's stock, valued at $6,382,293.42. Learn More on C. Frank Bennett's trading history.
Who are Ionis Pharmaceuticals' active insiders?
Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Shannon Devers (Executive Vice President, Chief Human Resources Officer), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Kyle Jenne (Executive Vice President, Chief Global Product Strategy Officer), Joseph Klein, III (Director), Holly Kordasiewicz (Executive Vice President, Chief Development Officer), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), Eric Swayze (EVP), and Joseph Wender (Director). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?
During the last year, insiders at the sold shares 89 times. They sold a total of 2,050,657 shares worth more than $146,114,376.98. The most recent insider tranaction occured on April, 16th when EVP Kyle Jenne sold 4,902 shares worth more than $368,483.34. Insiders at Ionis Pharmaceuticals own 2.7% of the company.
Learn More about insider trades at Ionis Pharmaceuticals. Information on this page was last updated on 4/16/2026.
